Skin Disease Education Foundation's (SDEF) 44th Annual Hawaii Dermatology Seminar is organized by Global Academy for Medical Education, LLC and will be held from Feb 16 - 21, 2020 at Hyatt Regency Maui Resort and Spa, Maui, Hawaii, United States of America.
This Conference is for you:
• Dermatology Residents
• Family Physicians
• Nurse Practitioners
• Physician Assistants
The University of Louisville School of Medicine designates this live activity for a maximum of 31.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This Live activity, Skin Disease Education Foundation's 44th Hawaii Dermatology Seminar, with a beginning date of 02/16/2020, has been reviewed and is acceptable for up to 31.5 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 31.5 contact hours (3.15 CEUs) of the Accreditation Council for Pharmacy Education. Type of Activity Application Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required. Universal Activity Number(s)- to be listed on the handout.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 31.5 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.
It will explore the latest advances in the treatment and management of common and complex diseases of the skin, both for adults and children as well as new developments in aesthetic medicine. Our exceptional faculty will present clinically relevant information that you will find immediately useful in the care of your patients. This six-day meeting provides interactive presentations, case studies in medical dermatology, live-patient injection sessions and multiple workshops. Learn from the experts about acne, rosacea, actinic keratoses, skin cancers, psoriasis, atopic dermatitis, nonsurgical facial rejuvenation, psoriatic arthritis, surgical pearls, and much more.
Skin Disease Education Foundation’s (SDEF) 44th Annual Hawaii Dermatology Seminar’s comprehensive agenda contains cutting edge, innovative and evolving issues relevant to practicing physicians and healthcare providers who treat diseases of the skin. Our scientific program has been designed to keep the clinician up-to-date on new developments within the field of dermatology.
At the conclusion of this live conference, participants should be better able to:
• Apply evidence-based pharmacologic and nonpharmacologic strategies to the management of patients with acne.
• Review current scientific findings that demonstrate the underlying pathophysiology of, and the treatment targets for, acne vulgaris.
• Discuss the factors that increase a patient’s risk for developing actinic keratosis.
• Design a treatment strategy for actinic keratosis that improves outcomes while minimizing the potential risk of complications.
• Discuss the benefits and risks of current agents and techniques commonly used in aesthetic and procedural dermatology.
• Select filler agents suitable for use in treating different facial areas.
• Design a nonsurgical treatment strategy, including potential use of neuromodulators, to address patient concerns about facial aging.
• Develop a treatment approach for atopic dermatitis that achieves the goal of clear or almost clear skin.
• Review safety and efficacy data on therapies that target the inflammatory component of atopic dermatitis.
• Compare and contrast the symptomatology of atopic dermatitis and the differences in the approach to treatment for adults vs pediatric patients.
• Recognize the role of dermoscopy in diagnosis and management of various skin lesions.
• List signs, symptoms, and diagnostic indicators of hidradenitis supparitiva severity levels and describe initial steps for treatment.
• Selectively treat patients based on an accurate diagnosis or refer patients for specialty care.
• Identify the conditions under which patients with hidradenitis supparitiva would be eligible for treatment with biologic therapies.
• Describe recent scientific findings that explicate the inflammatory basis of psoriasis.
• Discuss current clinical guidelines for optimal diagnosis and treatment of psoriasis.
• Review safety and efficacy data on new and emerging therapies for psoriasis.
• Implement a strategy for stepwise management of psoriasis with topical and biologic agents, including the use of treat-to-target goals.
• Apply current strategies for assessing and treating dermatologic conditions in pediatric patients, including acne, infections, birthmarks, hair disorders, and skin tumors.
• Identify when epicutaneous patch testing is appropriate in pediatric patients.
• Discuss safety and efficacy data on current and emerging therapies for rosacea.
• Define appropriate goals and strategies for the optimal management of patients with rosacea.
• Distinguish between benign nevi and suspicious neoplasms.
• Discuss available treatment strategies for melanoma at various stages of its progression.
• Identify high-risk tumor characteristics and indications for Mohs surgery and the impact of patient characteristics and expectations on the results of the procedure.
• Recognize the need for increased vigilance for the development of skin cancer in immunocompromised patients.
• Explain available methods for assessing and monitoring Spitz nevi.
• Describe available nonsurgical options for managing superficial nonmelanoma lesions.
• Define the underlying processes that lead to Merkel cell carcinoma, how recurrences can be diagnosed early, and resources for management.
• Discuss NCCN guidelines on melanoma surveillance, diagnostic tests and recurrence risk calculators.
• Describe techniques for managing keloids that offer the greatest benefits with minimal risk of scarring.
• Diagnose, and develop treatment strategies for hypopigmentation disorders.
• Discuss the latest data on the prevalence, severity, and impact of primary axillary hyperhidrosis and other common forms of hyperhidrosis.
• Outline strategies for diagnosing primary axillary hyperhidrosis and other forms of hyperhidrosis, including the use of validated instruments to assess the impact of the condition on affected patients.
• Review the evidence regarding the efficacy and safety profile of various first‐line and subsequent therapies for various types of hyperhidrosis, as well as patient candidacy for the different treatments.
Wednesday, February 19, 2020
|Contact No. :||561.777.9426
December 06, 2019
|Registration Type||End Date||Price|
|Physician and PhD Regular Fee||10 Jan,2020||USD 795.00|
|Physician and PhD Standard Fee||15 Feb,2020||USD 995.00|
|Physician and PhD Onsite Fee||16 Feb,2020||USD 1250.00|
|NP/PA/RN/Pharmacist Regular Fee||10 Jan,2020||USD 595.00|
|NP/PA/RN/Pharmacist Standard Fee||15 Feb,2020||USD 795.00|
|NP/PA/RN/Pharmacist Onsite Fee||16 Feb,2020||USD 995.00|
|Resident/Fellow Regular Fee||10 Jan,2020||USD 350.00|
|Resident/Fellow Standard Fee||15 Feb,2020||USD 400.00|
|Resident/Fellow Onsite Fee||16 Feb,2020||USD 500.00|
|Optional Conference Workshop (Open to Attendees Only) Regular Fee||10 Jan,2020||USD 95.00|
|Optional Conference Workshop (Open to Attendees Only) Standard Fee||15 Feb,2020||USD 95.00|
|Optional Conference Workshop (Open to Attendees Only) Onsite Fee||16 Feb,2020||USD 95.00|